Full Text:

Is There Anything Else We Could Possibly Need to Know About COX-2 Selective Inhibitor Drugs?

P. Davis, A. Juby, S. Robertson, N. Richard .........847

Articles

Functional Status and Radiographic Joint Damage Are Associated with Health Economic Outcomes in Patients with RA

A. Kavanaugh, C. Han, M. Bala .........849

Criteria for Improvement in RA: Alternatives to the ACR20

D.A. Albert, G. Huang, G. Dubrow, C.M. Brensinger, J.A. Berlin, H.J. Williams .........856

Glucocorticoids and Insulin Sensitivity in RA

P.H. Dessein, B.I. Joffe, A.E. Stanwix, B.F. Christian, M. Veller .........867

Increase of COX-2 Expression by IL-15 in Rheumatoid Synoviocytes

S-Y. Min, S-Y. Hwang, Y-O. Jung, et al .........875

Relative Sensitivity to Change of the ESR and Serum CRP Concentration in RA

M.M. Ward .........884

Radiation Synovectomy of the Ankle with 75 MBq Colloidal ¹⁸⁶Rhenium-Sulfide: Effect, Leakage, and Radiation Considerations

F.M. van der Zant, Z.N.Z. Jahangier, J.D. Moolenburgh, W. van der Zee, R.O. Boer, J.W.G. Jacobs .........896

Economic Evaluation of Folate Supplementation During MTX Treatment in RA

M. Hartman, A.E. van Ede, J.L. Severens, R.F.J.M. Laan, L.B.A. van de Putte, G.J. van der Wilt .........902

Duplex Study of the Carotid and Femoral Arteries of Patients with SLE: A Controlled Study

T. Wolak, E. Todosoui, G. Szendro, et al .........909

The Effect of Race on Disease Activity in SLE

N.O. Ghaussy, W.L. Sibbitt Jr, A.D. Bankhurst, C.R. Qualls .........915

Antibodies to Tissue Transglutaminase and Saccharomyces cerevisiae in AS and PsA

L. Riente, D. Chimenti, F. Pratesi, et al .........920

Unique Angiopathy After Herpes Virus Infection

J. Shimizu, A. Inatsu, S. Oshima, T. Kubota .........925

Development of the BD-QoL: A Quality of Life Measure Specific to Behçet's Disease

G. Gilworth, M.A. Chamberlain, B. Bhakta, D. Haskard, A. Silman, A. Tennant .........931

Resource Utilization in Postmenopausal Osteoporosis Without Incident Fractures

S.C. Kowalski, V.L. Sjenzfeld, M.B. Ferraz .........938

Immunogenicity of Hylan G-F 20 in Guinea Pigs and Mice

M. Sasaki, T. Miyazaki, T. Nakamura, T. Takahashi, S. Miyauchi, H. Iwata .........943

A Population Based Historical Cohort Study of the Mortality Associated with Nabumetone, Arthrotec, Diclofenac, and Naproxen

N.L. Ashworth, P.M. Peloso, N. Muhajarine, M. Stang .........951

Intraarticular Osteoid Osteoma: Clinical Features, Imaging Results, and Comparison with Extraarticular Localization

M. Szendroi, K. Köllo, I. Antal, J. Lakatos, G. Szoke .........957

Rheumatic Disease in an Australian Aboriginal Community in North Queensland, Australia. A WHO-ILAR COPCORD Survey

N. Minaur, S. Sawyers, J. Parker, J. Darmawan .........965

Significant Variation Exists in Home Care Services Following Total Joint Arthroplasty

N.N. Mahomed, J.T.C. Lau, M.K.S. Lin, R. Zdero, J.R. Davey .........973

Depressed Mood Impedes Pain Treatment Response in Patients with FM

A. Finset, S.H. Wigers, K.G. Götestam .........976

Pediatric Rheumatology

Assessment of Osteoporosis by Quantitative Ultrasound versus DEXA in Children with Chronic Rheumatic Diseases

C. Hartman, R. Shamir, O. Eshach-Adiv, G. Iosilevsky, R. Brik .........981

OPG/RANK-L System in JIA: Is There a Potential Modulating Role for OPG/RANK-L in Bone Injury?

L. Masi, G. Simonini, E. Piscitelli, et al .........986

NO-Derived Species in SF from Patients with JIA

A.P.N. Lotito, M.N. Muscará, M.H.B. Kiss, et al .........992

Another Patient with Chromosome 18 Deletion Syndrome and JRA

P. Rosen, R.J. Hopkin, D.N. Glass, T.B. Graham .........998

Case Report

Embolic Complications of a Mitral Valve Rheumatoid Nodule

H. Kang, M. Baron .........1001

Images in Rheumatology

Three-Dimensional Power Doppler Sonographic Visualization of Synovial Angiogenesis in RA

J. Strunk, U. Lange .........1004

Correspondence

The Fate of Abstracts: Without Publication, Science Is Dead A. Olivé, I. Cifuentes, J. Roca .........1007

Reply P.J. Hashkes, Y. Uziel .........1007

Serious GI Events from Low Dose Analgesic Use R.E. Tarone, L. Lipworth, J.K. McLaughlin .........1008

Letter D.A. Peura .........1009

Reply J.F. Fries, B. Bruce .........1010

Ophthalmologic Monitoring for Antimalarial Toxicity P.P. Sfikakis, M. Mavrikakis .........1011

Reply S. Bernatsky, C. Pineau, M. Gans, A. Clarke .........1012

Diagnostic Value of Anticyclic Citrullinated Peptide Antibody in RA T.L.T.A. Jansen, G.A.W. Bruyn .........1012

Reply X. Zeng .........1013

Prevalence of Silent Amyloidosis in RA and Its Clinical Significance R. Sanmartí, E. Gómez-Casanovas, M. Solé, et al 1013

Reply R. Misra, A. Wakhlu, N. Krishnani, P. Hissaria, A. Aggarwal .........1014

Macrophage Activation Syndrome Due to MTX in a 12-year-old Boy with Dermatomyositis G. Sterba, C. Rodriguez, S. Sifontes, P. Vigilanza .........1014

Reply A. Ravelli, A. Martini .........1015

Breast Implant Related Disease B. Rothschild, M. Helbling II .........1015

Reply R.C.W. Vermeulen, H.R. Scholte .........1015

Letters

Hepatitis C Virus and RA: Further Pieces to the Puzzle A. Csepregi, G. Poór, E. Nemesánszky 1016

Etanercept in Breast Milk M. Ostensen, G.O. Eigenmann .........1017

Severe Recurrent Neurological Disease in the MAGIC Syndrome E. Gertner .........1018

Correction

Rheumatoid Arthritis Treatment with Weekly Leflunomide: An Open-Label Study J. Jaimes-Hernández, M. Robles-San Román, R. Suárez-Otero, M.E. Dávalos-Zugasti, S. Arroyo-Borrego .........1019

Notices